RY 161.29 0.8315% SHOP 116.7 1.6108% TD 83.65 0.553% ENB 61.82 1.2613% BN 68.755 0.8729% TRI 248.88 1.754% CNQ 38.22 0.6054% CP 103.1 0.4775% CNR 138.9 -0.0576% BMO 129.44 1.1013% BNS 65.52 0.7845% CSU 4654.3901 1.9582% CM 81.81 1.3755% MFC 40.37 1.0766% ATD 69.68 -0.9805% NGT 76.14 0.2106% TRP 67.93 2.0123% SU 46.68 0.4735% WCN 273.82 0.8397% L 206.99 -1.499%
Last update at 2025-04-15T16:58:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
BioNTech (NasdaqGS:BNTX) Sees 11% Stock Increase Over Last Week
Mon 14 Apr 25, 05:34 PMZai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?
Mon 14 Apr 25, 01:10 PMBarbara Weber, M.D., Elected to ITM Supervisory Board
Wed 09 Apr 25, 09:00 AMIs BioNTech SE (BNTX) the Best German Stock to Buy According to Hedge Funds?
Wed 02 Apr 25, 07:37 PMModerna, biotech stocks slide following resignation of FDA official Peter Marks
Mon 31 Mar 25, 01:57 PMGSK accuses Pfizer of delaying Covid vaccine result until after US election
Thu 27 Mar 25, 02:06 PMIs BioNTech SE (BNTX) a Promising Biotech Stock According to Wall Street Analysts
Tue 25 Mar 25, 09:40 PMBioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Sun 16 Mar 25, 01:38 PMCiti says SMid biotechs alternative to large caps as it starts coverage
Thu 13 Mar 25, 03:34 PM| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | 1186.10M | 12954.10M | 15046.40M | -145.80200M | -179.44000M |
| Minority interest | - | - | 0.00000M | 0.00000M | 0.12M |
| Net income | 930.30M | 9434.40M | 10292.50M | 15.20M | -179.17200M |
| Selling general administrative | 495.00M | 484.70M | 278.50M | 94.05M | 40.69M |
| Selling and marketing expenses | 62.70M | 59.50M | 50.40M | 14.51M | 2.72M |
| Gross profit | 3219.20M | 12778.60M | 15116.00M | -222.03700M | -135.23800M |
| Reconciled depreciation | 183.40M | 123.30M | 75.20M | 38.74M | 33.90M |
| Ebit | 972.00M | 12642.70M | 15283.80M | -82.41700M | -181.51800M |
| Ebitda | 1155.40M | 13096.30M | 14970.70M | -42.10900M | -146.16700M |
| Depreciation and amortization | 183.40M | 453.60M | -313.10000M | 40.31M | 35.35M |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 690.40M | 12642.70M | 15283.80M | -82.41700M | -181.51800M |
| Other operating expenses | 2914.80M | 4667.90M | 4060.80M | 564.74M | 290.11M |
| Interest expense | 7.74M | 18.90M | 5.40M | 64.95M | 1.72M |
| Tax provision | 255.80M | 3519.70M | 4753.90M | -161.00000M | -0.26800M |
| Interest income | 357.60M | 330.30M | 1.50M | 1.56M | 1.78M |
| Net interest income | 349.70M | 311.40M | -25.80000M | -3.48700M | -0.26300M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 255.80M | 3519.70M | 4753.90M | -161.00000M | -0.26800M |
| Total revenue | 3819.00M | 17310.60M | 18976.70M | 482.32M | 108.59M |
| Total operating expenses | 2315.00M | 135.90M | 200.10M | -139.62000M | 46.28M |
| Cost of revenue | 599.80M | 4532.00M | 3860.70M | 704.36M | 243.83M |
| Total other income expense net | -67.80000M | 311.40M | -237.40000M | -63.38500M | 2.08M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 930.30M | 9434.40M | 10292.50M | 15.20M | -179.17200M |
| Net income applicable to common shares | - | - | 10292.50M | 15.20M | -179.05600M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 23006.30M | 23279.10M | 15830.80M | 2318.62M | 797.65M |
| Intangible assets | 804.10M | 158.50M | 144.60M | 109.79M | 86.46M |
| Earning assets | - | - | - | - | - |
| Other current assets | 280.90M | 271.90M | 64.90M | 60.97M | 1.18M |
| Total liab | 2760.40M | 3223.50M | 3937.10M | 946.77M | 304.15M |
| Total stockholder equity | 20245.90M | 20055.60M | 11893.70M | 1371.85M | 493.49M |
| Deferred long term liab | - | - | 13.60M | - | 0.00000M |
| Other current liab | 1335.10M | 2633.40M | 3002.60M | 103.05M | 16.44M |
| Common stock | 248.60M | 248.60M | 246.30M | 246.31M | 232.30M |
| Capital stock | 248.60M | 248.60M | 246.30M | 246.31M | 232.30M |
| Retained earnings | 19763.30M | 18833.00M | 9882.90M | -409.62900M | -424.82700M |
| Other liab | - | - | 283.90M | 109.71M | 97.11M |
| Good will | 362.50M | 61.20M | 57.80M | 53.70M | 2.98M |
| Other assets | - | 249.20M | 22.20M | 168.23M | 2.40M |
| Cash | 11663.70M | 13875.10M | 1692.70M | 1210.21M | 519.15M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2070.50M | 2950.60M | 3481.60M | 606.01M | 138.14M |
| Current deferred revenue | 353.30M | 77.10M | 189.10M | 391.53M | 93.58M |
| Net debt | -11444.60000M | -13662.90000M | -1391.20000M | -970.02000M | -450.24500M |
| Short term debt | 28.10M | 36.00M | 129.90M | 9.14M | 7.62M |
| Short long term debt | 28.10M | 36.00M | 129.90M | 9.14M | 0.00000M |
| Short long term debt total | 219.10M | 212.20M | 301.50M | 240.19M | 68.90M |
| Other stockholder equity | 1218.60M | -5.30000M | -3.80000M | 1509.66M | -5.52500M |
| Property plant equipment | - | - | 520.40M | 325.96M | 148.06M |
| Total current assets | 19527.30M | 21922.00M | 15072.30M | 1666.90M | 560.15M |
| Long term investments | 1176.10M | 80.20M | 21.30M | - | 0.00000M |
| Net tangible assets | - | - | 11699.10M | 1214.31M | 406.46M |
| Short term investments | 4885.30M | 189.40M | 381.60M | 137.23M | 1.68M |
| Net receivables | 2339.70M | 7146.00M | 12382.10M | 166.37M | 20.20M |
| Long term debt | 191.00M | 176.20M | 171.60M | 231.05M | 68.90M |
| Inventory | 357.70M | 439.60M | 502.50M | 64.12M | 11.72M |
| Accounts payable | 354.00M | 204.10M | 160.00M | 102.29M | 20.50M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | -984.60000M | 979.30M | 1768.30M | 25.50M | 691.54M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | 246.31M | 232.30M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | -5.52500M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 83.40M | 6.50M | 0.80M | 1.04M | 0.00200M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 3479.00M | 1357.10M | 758.50M | 651.72M | 237.50M |
| Capital lease obligations | - | - | - | - | 0.00000M |
| Long term debt total | - | - | - | - | 68.90M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -6954.50000M | -35.30000M | -566.10000M | -144.84800M | -77.11500M |
| Change to liabilities | - | - | 1516.10M | 204.58M | -80.57700M |
| Total cashflows from investing activities | - | - | -566.10000M | -144.84800M | -77.11500M |
| Net borrowings | - | - | -66.70000M | 141.72M | 7.94M |
| Total cash from financing activities | -778.60000M | -1419.30000M | 94.20M | 894.73M | 383.29M |
| Change to operating activities | - | - | - | - | 0.00000M |
| Net income | 1186.10M | 12954.10M | 15046.40M | -145.80200M | -179.44000M |
| Change in cash | -2211.40000M | 12182.40M | 482.50M | 691.06M | 107.65M |
| Begin period cash flow | 13875.10M | 1692.70M | 1210.20M | 519.15M | 411.50M |
| End period cash flow | 11663.70M | 13875.10M | 1692.70M | 1210.21M | 519.15M |
| Total cash from operating activities | 5371.40M | 13577.40M | 889.70M | -13.47400M | -198.53700M |
| Issuance of capital stock | 0.00000M | 110.50M | 160.90M | 753.01M | 375.35M |
| Depreciation | 183.40M | 123.30M | 75.20M | 38.74M | 33.90M |
| Other cashflows from investing activities | - | - | - | - | -6.03500M |
| Dividends paid | 0.00000M | 484.30M | 0.00000M | 0.00000M | 0.00000M |
| Change to inventory | 81.90M | 62.90M | -438.40000M | -49.79400M | -5.79800M |
| Change to account receivables | 5263.84M | 4369.90M | -11808.10000M | -247.88600M | 2.94M |
| Sale purchase of stock | -738.50000M | -986.40000M | 0.00000M | 0.00000M | 375.35M |
| Other cashflows from financing activities | 0.30M | 0.80M | -566.10000M | 156.03M | 11.00M |
| Change to netincome | - | - | 1252.40M | 25.68M | 30.06M |
| Capital expenditures | 705.50M | 363.30M | 154.00M | 85.45M | 71.08M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | 5574.80M | 4518.50M | -10730.40000M | -93.09700M | -83.43600M |
| Stock based compensation | 51.40M | 108.60M | 93.90M | 32.10M | 30.23M |
| Other non cash items | -1275.50000M | -4127.10000M | 212.50M | 114.47M | 0.26M |
| Free cash flow | 4665.90M | 13214.10M | 735.70M | -98.92000M | -269.61700M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE |
-3.645 3.56% | 98.69 | 192.04 | 7.04 | 5.46 | 0.96 | 0.87 | 3.06 |
| NVO Novo Nordisk A/S |
-1.6397 2.48% | 64.42 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.68 1.04% | 65.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.97 0.20% | 496.80 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-11.3354 1.99% | 559.72 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
An der Goldgrube 12, Mainz, Germany, 55131
| Name | Title | Year Born |
|---|---|---|
| Prof. Ugur Sahin M.D. | Co-Founder, CEO & Chair of the Management Board | 1965 |
| Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer & Member of Management Board | 1967 |
| Prof. Christoph Hubert Huber M.D., Ph.D. | Co-Founder & Member of Supervisory Board | 1944 |
| Mr. Jens H. Holstein | CFO & Member of Management Board | 1963 |
| Dr. Sierk Poetting Ph.D. | MD, COO & Member of Management Board | 1973 |
| Mr. Ryan Richardson | Chief Strategy Officer, MD & Member of Management Board | 1979 |
| Mr. Sean Marett | Chief Bus. Officer, Chief Commercial Officer & Member of Management Board | 1965 |
| Sylke Maas Ph.D. | VP of Investor Relations and Bus. Strategy | NA |
| Dr. James Timothy Patrick Ryan Ph.D. | Sr. VP & Gen. Counsel | NA |
| Michael Boehler | MD & Head of Global External Communications | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA
NZ
UK
US
AU
IND
Please wait processing your request...